Extract
磷酸二酯酶5抑制剂(PDE5I),例如西地那非和他达拉非,经常用于治疗肺动脉高压(PAH)[1]。PDE5I的联合疗法与药物作用via其他信号机制,i.e.the endothelin pathway, is currently recommended as it provides better clinical outcomes than monotherapy with PDE5i [1, 2]. The soluble guanylyl cyclase (sGC) stimulator riociguat is an interesting alternative to PDE5i, with a different mode of action but on the same signalling pathway. Recently, the results of the REPLACE study show that, in patients remaining at intermediate risk of 1-year mortality after PDE5i treatment, switching to riociguat is beneficial in terms of clinical improvement and risk status as compared with PDE5i maintenance therapy [3].
抽象的
Vitamin D deficiency causes a reduced response to sildenafil but not to riociguat in rats with PAH. Lower levels of vitamin D were also retrospectively associated to insufficient response to PDE5 inhibitors in PAH patients.https://bit.ly/3rZDcTF
脚注
All individual participant data that underlie the results reported in this article will be available on request.
Conflict of interest: M. Callejo has no competing interests.
Conflict of interest: I. Blanco has received honoraria from Actelion, Janssen and MSD.
Conflict of interest: J.A. Barberá has received grants and honoraria from Actelion, Janssen, MSD and GSK.
Conflict of interest: F. Perez-Vizcaino has received a lecture fee from Actelion.
Support statement: This study was supported by grants from Ministerio de Economía y Competitividad (SAF2016-77222-R and PID2019-107363RB-I00) and Fundación Contra la Hipertensión Pulmonar (Empathy), and an unrestricted grant from MSD. Funding information for this article has been deposited with theCrossref Funder Registry.
- 已收到2021年4月27日。
- AcceptedJuly 28, 2021.
- 复制right ©The authors 2021. For reproduction rights and permissions contactpermissions{at}ersnet.org